Ardea Biosciences, Inc. (RDEA)

[surf1944]

Ardea HIV Drug Meeting Study Goals
Monday March 17, 5:40 pm ET
Ardea Biosciences' Developing HIV Treatment Is Meeting Midstage Study Goals

SAN DIEGO (AP) -- Ardea Biosciences Inc. said Monday its developing HIV treatment is meeting goals in a midstage clinical trial and the program is on track to move to a new stage in the second quarter.

The drug candidate, RDEA806, showed positive results in a Phase 2a study comparing the drug candidate with placebo, according to preliminary results. The company said it plans on moving the drug candidate into a Phase 2b clinical trial during the second quarter. That study would also focus on safety and effectiveness and would compare the experimental drug with Bristol-Myers Squibb Co.'s Sustiva.

Shares of Ardea Biosciences rose 9 cents to close at $12.99.